Pro-Dex Corp (PDEX) - Forward Price-to-Revenue Multiple

pro-dex.com (PDEX) - corporate logo

The stability of Pro-Dex, Inc. (PDEX) relies on long-term agreements with market leaders, with 3.00 serving as the base parameter value. The expected price-to-sales ratio visualizes the balance between demand and revenue forecasts. This trend is supported by the development of smart actuators through partnerships with OEM brands and deep expertise in maxillofacial surgery, enabling the rapid modernization of high-precision instruments to meet clinic requirements.

PDEX pro-dex.com: Forward Price-to-Revenue Multiple in the range 07/04/2022 - 11/13/2026

Pro-Dex Inc. - analytical breakdowns and key metrics (PDEX)

- market price and analyst price targets:
- market capitalization indicators:
General company analysis:PDEX (Pro-Dex)
Original product of pro-dex.com

The forward P/S reflects the market value of Pro-Dex, Inc. (PDEX) relative to expected future sales, allowing investors to assess the premium paid for every dollar of revenue. By analyzing P/S expectations for Pro-Dex, Inc. (PDEX) on GURU.Markets, one can correlate the multiple's dynamics with the volume of orthopedic surgeries and the stability of OEM contracts, which determine the real scaling potential of the business within the medical sector.

Analysis of competing companies

Price-to-Projected Revenue Ratio Intuitive ISRG|Forward Price to Sales DHR|BDX: Forward Price-to-Revenue Multiple|STE - Forward P/S Multiple|West Pharmaceutical Services (WST) - Price-to-Projected Revenue Ratio|Forward Price-to-Revenue Multiple baxter.com|MASI (Masimo) - Forward P/S Multiple|Market Cap to Future Revenue Ratio Stevanato Group SpA STVN|Price-to-Projected Revenue Ratio Teleflex Inc (TFX)|Merit Medical Corp - Market Cap to Projected Revenue|Envista Holdings - Forward Price-to-Revenue Multiple|Price to Expected Revenue Ratio ICUI (icumed.com)|XRAY - Price-to-Projected Revenue Ratio|Market Cap to Expected Sales Ratio LeMaitre Vascular Inc LMAT|AtriCure Corp (ATRC) - Price-to-Projected Revenue Ratio|Future Price to Revenue STAA (STAAR Surgical Co)|Price-to-Projected Revenue Ratio ChromaDex Corporation|ZIMV: Forward Price to Sales|Price-to-Projected Revenue Ratio AngioDynamics (ANGO)|CERS - Market Cap to Future Revenue Ratio|Alpha Teknova Inc - Forward Price-to-Revenue Multiple|Projected Price to Revenue Monogram Orthopedics Inc.|Sharps Tech - Forward P/S Multiple|INFU (InfuSystem Holdings) - Market Cap to Projected Revenue|UTMD: Forward P/S Multiple|Market Cap to Future Revenue Ratio KORU Medical (KRMD)|Forward Price-to-Revenue Multiple NYXH|Market Cap to Projected Revenue MBOT (Microbot Medical, Inc)|Forward Price-to-Revenue Multiple ZTEK (Zentek Ltd.)|ELUT (elutia.com) - Forward Price to Sales|Forward P/S Multiple MLSS (Milestone Scientific Inc.)|Market Cap to Expected Sales Ratio NEXGEL Inc. (NXGL)|RVP - Price-to-Projected Revenue Ratio|HBIO (harvardbioscience.com) - Market Cap to Projected Revenue|FEMY: Forward P/S Multiple|Forward Price-to-Revenue Multiple Meihua Medical Technologies Co., Ltd.|Forward Price-to-Revenue Multiple POAI|Callan JMB Corp (CJMB) - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Atrion Corp (ATRI)|NURO: Future Price to Revenue